Patients get extreme to obtain hepatitis drug that's 1 percent the cost outside US
Having trouble reading this email? View online.


Archive Volume 16, Issue 4 September/October 2015
Published by the Hemophilia Association of the Capital Area | HACAcares.org


Once-a-week HIV injections may free millions from pills
Voice of America

An injectable HIV treatment is entering advanced clinical trials, potentially freeing millions of men and women living with the virus from pills. Developers say the once-a-week injections could help people living with HIV lead more normal lives.


Multiple HIV-1 variants at the beginning of infection impact viral load setpoints
News Medical

HIV-1 infection with multiple founder variants points to poorer clinical outcomes than infection with a single variant, according to a paper published today in the journal Nature Medicine.


Hepatitis C cure associated with significant improvement in liver stiffness in people with HIV and HCV co-infection
Aidsmap

A successful response to hepatitis C virus therapy is associated with a significant improvement in liver stiffness among people with HIV and HCV co-infection, French investigators report in the online edition of AIDS. Patients were followed for an average of 45 months, and significant regression of liver stiffness from pretreatment levels was observed in successful responders with fibrosis and cirrhosis. Liver stiffness is considered to be a good non-invasive marker of liver fibrosis stage.


Discovery allows study of naturally occurring forms of HCV in the lab
News Medical

Worldwide, 185 million people have chronic hepatitis C. Since the late 1980s, when scientists discovered the virus that causes the infection, they have struggled to find ways to grow it in human cells in the lab — an essential part of learning how the virus works and developing new effective treatments.


One in four hepatitis C patients denied initial approval for drug treatment
YaleNews

Nearly one in four patients with chronic hepatitis C are denied initial approval for a drug therapy that treats the most common strain of the infection, according to a Yale School of Medicine study. The finding, published Aug. 27 in PLOS ONE, identifies a new barrier to caring for patients with this severe condition.


Hepatitis C associated with higher heart disease risk
HCPLive

It is well-known that patients with hepatitis C face a higher risk of liver complications; however, a new study discovered that the heart could also be in trouble. Eric Seaberg, Ph.D., and colleagues from the Johns Hopkins Bloomberg School of Public Health found strong evidence suggesting that patients with hepatitis C are also at a higher risk for heart disease.



HCV/HIV Today
Hemophilia Association of the Capital Area

Mailing Address
10560 Main Street, Suite 309
Fairfax, VA 22030
Office Phone
703-352-7641
Fax
540-427-6589
Email
admin@HACAcares.org


This email was sent by the Hemophilia Association of the Capital Area, powered by Powered by Corporate Briefs
Engage your customer base. Launch your Corporate Brief today.

Archive | View Online